March 03, 2025

More States Fast Track Foreign-Trained Physicians

Since 2023, nine states have waived U.S. residency requirements for some foreign-trained physicians, with more states considering similar changes.

KFF Health News

March 03, 2025

FDA Approves First New Stroke Thrombolytic in 30 Years

The FDA has approved tenecteplase for acute ischemic stroke, offering a faster and simpler administration compared to alteplase based on findings from the AcT trial.

Conexiant

February 27, 2025

CDC Investigating Hospitalizations After Chikungunya Vaccine

Health care providers are advised to assess the benefits and risks of the vaccine with each traveler.

Conexiant

February 24, 2025

Game-Changer for Pfizer? Former FDA Drug Chief Takes Reins

Before leadership at the FDA, Dr. Patrizia Cavazzoni spent nearly 2 decades in the pharmaceutical industry.

Conexiant

February 24, 2025

FDA Approves Medtronic Adaptive Deep Brain Stimulation System

The BrainSense Adaptive deep brain stimulation system is the first FDA-approved closed-loop neuromodulation therapy designed to automatically adjust stimulation in real time based on individual brain activity for patients with Parkinson’s disease.

Conexiant

February 12, 2025

FDA Approves Mirdametinib for NF1-Associated Plexiform Neurofibromas

Data from the phase III ReNeu trial showed the kinase inhibitor led to an overall response rate of 41% in adult patients and 52% in pediatric patients.

Conexiant

February 12, 2025

Phase III Trial Targets Venous Leg Ulcers

With no new FDA-approved drugs for chronic wound debridement since 1965, MediWound's phase 3 trial tests EscharEx for venous leg ulcers in 216 patients.

Reuters

February 12, 2025

FDA Approves Evrysdi Tablet for SMA Treatment

FDA approves Roche’s Evrysdi tablet for spinal muscular atrophy, which offers a noninvasive, room-temperature stable treatment option.

Conexiant

February 11, 2025

FDA Approves Mirdametinib for Neurofibromatosis Type 1

The FDA has approved mirdametinib (Gomekli), a kinase inhibitor, for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibroma...

The ASCO Post